...
首页> 外文期刊>Journal of Clinical Microbiology >Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests
【24h】

Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests

机译:AMPLICOR和COBAS AMPLICOR丙型肝炎病毒检测的前瞻性多中心临床评估

获取原文
           

摘要

We conducted a multicenter clinical evaluation of the second versions of the manual AMPLICOR and the semiautomated COBAS AMPLICOR tests for hepatitis C virus (HCV) RNA (Roche Molecular Systems, Inc., Pleasanton, Calif.). The performance characteristics of these HCV RNA tests for diagnosis of active viral infection were determined by comparison to anti-HCV serological test results, alanine aminotransferase levels, and liver biopsy histology results. A total of 878 patients with clinical or biochemical evidence of liver disease were enrolled at four hepatology clinics. A total of 1,089 specimens (901 serum and 188 plasma) were tested with the AMPLICOR test. Sensitivity compared to serology was 93.1% for serum and 90.6% for plasma. The specificity was 97% for serum and 93.1% for plasma. A total of 1,084 specimens (896 serum and 188 plasma) were tested with the COBAS test. Sensitivities for serum and plasma were the same as with the AMPLICOR test. The specificity was 97.8% for serum and 96.6% for plasma. Of the 69 specimens with false-positive and false-negative AMPLICOR test results relative to those of serology, alternative primer set (APS) reverse transcription (RT)-PCR analysis showed that the AMPLICOR test provided the correct result relative to the specimens containing HCV RNA in 64 (92.7%) specimens. Similarly, 66 of 67 (98.5%) false-positive and false-negative COBAS test results were determined to be correct by APS RT-PCR analysis. There were no substantive differences in clinical performances between study sites, patient groups, specimen types, storage conditions (?20 to ?80°C versus 2 to 8°C), or anticoagulants (EDTA versus acid citrate dextrose) for either test. Both tests showed >99% reproducibility within runs, within sites, and overall. We conclude that these tests can reliably detect the presence of HCV RNA, as evidence of active infection, in patients with clinical or biochemical evidence of liver disease.
机译:我们对第二版手册AMPLICOR和半自动COBAS AMPLICOR检测丙型肝炎病毒(HCV)RNA(罗氏分子系统有限公司,加利福尼亚州普莱森顿)进行了多中心临床评估。通过与抗HCV血清学检测结果,丙氨酸转氨酶水平和肝活检组织学结果进行比较,确定了这些HCV RNA检测用于诊断活动性病毒感染的性能特征。在四家肝病诊所中,共有878名具有肝脏疾病临床或生化证据的患者入组。用AMPLICOR测试测试了1,089个样本(901个血清和188个血浆)。与血清学相比,血清学敏感性为93.1%,血浆学敏感性为90.6%。血清特异性为97%,血浆特异性为93.1%。用COBAS测试测试了总共1,048个样本(896个血清和188个血浆)。血清和血浆的敏感性与AMPLICOR测试相同。血清特异性为97.8%,血浆特异性为96.6%。在AMPLICOR测试结果相对于血清学为假阳性和假阴性的69个标本中,替代引物组(APS)反转录(RT)-PCR分析表明,AMPLICOR测试相对于含HCV的标本提供了正确的结果64(92.7%)个样本中的RNA。同样,通过APS RT-PCR分析,在67例(98.5%)假阳性和假阴性COBAS测试结果中,有66例是正确的。两种测试的研究地点,患者组,标本类型,储存条件(?20至?80°C与2至8°C)或抗凝剂(EDTA与柠檬酸右旋糖)之间的临床表现均无实质性差异。两项测试均显示运行,站点内和总体上的重复性均> 99%。我们得出的结论是,这些测试可以在具有肝脏疾病的临床或生化证据的患者中可靠地检测出HCV RNA的存在,以此作为主动感染的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号